Expert Panel describes path to bring critical antibiotics to Canadian market
Canada is lagging behind peer countries on access to existing drugs, and a new expert panel report describes a pathway to a more stable supply of antimicrobials in the future.
- Canada is lagging behind peer countries on access to existing drugs, and a new expert panel report describes a pathway to a more stable supply of antimicrobials in the future.
- “The consequences of antimicrobial resistance are real and growing, while at the same time, companies are leaving the commercial space,” said Andrew M. Morris, M.D., Chair of the Expert Panel.
- The cumulative costs to Canadian healthcare systems could reach $120 billion by 2050 as resistance rates increase.
- Overcoming Resistance describes the challenges Canada faces when accessing high-value antimicrobials and describes pull incentives that could help bring existing antimicrobials to market and encourage the development of new ones.